2025 ESMO GI | 中国智慧闪耀国际:入选研究一览
2025-06-27 来源:医脉通消化系统肿瘤
关键词: 2025 ESMO GI

一年一度的欧洲肿瘤内科学会胃肠肿瘤年会(ESMO GI)将于2025年7月2日~5日在巴塞罗那召开。日前,大会官网披露了摘要标题,其中34项中国研究入选。医脉通整理如下,和您一起先睹为快!


食管癌


1. 摘要号:394P


研究名称(英文):Reactive cutaneous capillary endothelial proliferation in esophageal squamous cell carcinoma patients treated with camrelizumab-based therapy: a pooled analysis of two phase 3 trials    

讲者:骆卉妍 | 中山大学肿瘤防治中心


2. 摘要号:396P


研究名称(英文):A single-arm phase II study of cabozantinib and atezolizumab in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M ESCC) who failed platinum-based chemotherapy    

讲者:Hung-Yang Kuo | 台湾大学医学院附设医院


3. 摘要号:399P


研究名称(英文):ARL5B Drives Esophageal Squamous Cell Carcinoma Progression via ROCK1-SREBP1 Mediated Metabolic Reprogramming    

讲者:Xinyue Ma | 山东大学齐鲁医院


4. 摘要号:418P


研究名称(英文):Real-world Outcomes of First-line Nivolumab for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Multicenter, Retrospective, Observational Study    

讲者:邱红 | 华中科技大学同济医学院附属同济医院


5. 摘要号:419P


研究名称(英文):Real-world Treatment Pattern and Biomarker Testing Landscape of Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC) in China (SURPASS Study)

讲者:Rongrui Liu | 中国人民解放军总医院


6. 摘要号:424P


研究名称(英文):Chemotherapy (SOX) plus Tisleizumab in Gastric cancer patients with liver metastasis: the first report from a multi-center phase II study    

讲者:康牧星 | 浙江大学医学院附属第二医院


7. 摘要号:430P


研究名称(英文):Decoding the Responsive and Resistant Features to the Claudin18.2-specific CAR-T cell CT041 in Gastric Cancer: An Exploratory Biomarker Analysis of the Phase 1 Clinical Trial    

讲者:彭昊昕 | 北京大学肿瘤医院


8. 摘要号:436P


研究名称(英文):Hepatic resection improves the prognosis of gastric cancer liver metastasis patients with resected primary lesions

讲者:Yun Feng | 复旦大学附属肿瘤医院


肝胆胰肿瘤


1. 摘要号:LBA2


研究名称(英文):TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC)    

讲者:韩国宏 | 西安国际医学中心医院


2. 摘要号:149MO


研究名称(英文):Irpagratinib (ABSK-011) plus Atezolizumab in First-line (1L) and Immune Checkpoint Inhibitors (ICIs) Treated Advanced Hepatocellular Carcinoma (HCC) with FGF19 Overexpression (+): Updated Results of the Phase 2 ABSK-011-201 Study

讲者:程琪 | 华中科技大学同济医学院附属同济医院


3. 摘要号:150MO


研究名称(英文):Safety results from the Phase 3b SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for hepatocellular carcinoma (HCC) participants (pts) with a poor prognosis

讲者:Stephen L. Chan | 香港中文大学


4. 摘要号:157P


研究名称(英文):Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment in Chinese patients with unresectable/advanced hepatocellular carcinoma (HCC): CheckMate 9DW expanded analyses    

讲者:秦叔逵| 中国药科大学附属南京天印山医院


5. 摘要号:183P


研究名称(英文):Comparison of the prognostic value of NLR with PLR, LMR, SII, and PNI in HCC patients undergoing cryoablation and its application in the best applicable population

讲者:李家平 | 中山大学附属第一医院


6. 摘要号:195P


研究名称(英文):Bioinformatics and system biology approach to identify the influences among COVID-19, cirrhosis and hepatocellular carcinoma

讲者:Xianxiang Chen | 广西医科大学第一附属医院


7. 摘要号:203eP


研究名称(英文):Cell-free DNA (cfDNA) Biomarkers and AI Models for Early Detection of Liver Cancer: A Systematic Review and Meta-Analysis

讲者:Minh Le | 台北医学大学


8. 摘要号:206eP


研究名称(英文):Prognostic Influence of Baseline ALBI Grade on Treatment Outcomes in Hepatocellular Carcinoma Patients Receiving Lenvatinib

讲者:商昌珍 | 中山大学孙逸仙纪念医院


9. 摘要号:209eP


研究名称(英文):RPL41 Promotes HCC Metastasis Via Transcription Factors RUNX2-Mediated EMT Mechanism

讲者:Zheng Hua | 重庆大学附属沙坪坝医院


10. 摘要号:302P


研究名称(英文):Surufatinib plus gemcitabine and nab-paclitaxel for neoadjuvant therapy in resectable and borderline resectable pancreatic cancer

讲者:高松 | 天津市肿瘤医院


11. 摘要号:313P


研究名称(英文):ABHD17C-mediated S-depalmitoylation of BCL6B enhances CD24 transcription to resist macrophage phagocytosis in pancreatic cancer

讲者:Yalu Zhang | 中国科学技术大学附属第一医院


12. 摘要号:317P


研究名称(英文):Tumor-Microenvironment-on-Chip: A Real-Time Window into Immunotherapy Efficacy under Heterogeneity

讲者:Chiao-Min Lin | 台湾清华大学


13. 摘要号:358P


研究名称(英文):Comparative Effectiveness of Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancer: A Single-Center Retrospective Cohort Study

讲者:Wen-Ying Lin | 台北荣民总医院


结直肠癌


1. 摘要号:LBA1


研究名称(英文):Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Non-Metastatic Colorectal Cancer: Interim Analysis of FIND Trial

讲者:彭俊杰 | 复旦大学附属肿瘤医院


2. 摘要号:11P


研究名称(英文):NALIRIFOX Plus Targeted Therapy as First-Line Treatment for Metastatic Colorectal Cancer: A Phase I Study

讲者:Haojie Zhou | 复旦大学附属中山医院


3. 摘要号:49P


研究名称(英文):A multicentre propensity score matched analysis comparing maintenance strategies and treatment-break after first-line induction therapy for metastatic colorectal cancer

讲者:Connie Ka Yan Lai | 伊利沙伯医院


4. 摘要号:65P


研究名称(英文):BETTER Study: An Open-Label, Single-Arm Trial of Tislelizumab, Bevacizumab, TAS102, and SBRT as Third-Line Therapy for MSS/pMMR Metastatic Colorectal Cancer 

讲者:张群 | 南京鼓楼医院


5. 摘要号:98P


研究名称(英文):A novel risk-stratification model with molecular markers for predicting early colorectal cancer invasion depth

讲者:Bing Li | 复旦大学


6. 摘要号:130eP


研究名称(英文):From Evidence to Practice: A Multicenter Real-World Study and Meta-Analysis of Immunotherapy in MSS/MSI-L Colorectal Cancer

讲者:Yue Gou | 中南大学


7. 摘要号:131eP


研究名称(英文):Efficacy and safety of triple-therapy with bevacizumab, oxaliplatin, with irinotecan for metastatic colorectal cancer failed with previous fluorouracil-centered treatment

讲者:韩璐 | 中国人民解放军总医院第五医学中心


8. 摘要号:139eP


研究名称(英文):Real-World Practice of MSI/MMR Testing and Treatment Patterns in Colorectal Cancer: A Nationwide Survey in China (SUMMER Study)

讲者:王正航 | 北京大学肿瘤医院


9. 摘要号:146TiP


研究名称(英文):MIRACLE3: Phase II study of Ivonescimab plus radiotherapy and chemotherapy as first-line treatment in MSS colorectal cancer patients with unresectable liver/lung metastases — Trial in progress

讲者:李心翔 | 复旦大学附属肿瘤医院


10. 摘要号:224P


研究名称(英文):Short-course radiotherapy followed by sintilimab and CAPOX as total neoadjuvant treatment in locally advanced rectal cancer: a prospective, randomized controlled trial (SPRING-01)

讲者:Feng Tian | 山东第一医科大学附属省立医院


11. 摘要号:226P


研究名称(英文):Adebrelimab Combined with Short-Course Radiotherapy and CAPOX as Total Neoadjuvant Therapy for pMMR Locally Advanced Rectal Cancer: Interim Results

讲者:靖昌庆 | 山东第一医科大学附属省立医院


12. 摘要号:229P


研究名称(英文):Randomized study of neoadjuvant chemoradiotherapy with or without intensification with FOLFOXIRI for high-risk locally advanced rectal cancer - clinical and quality of life analysis (NCT03997435)

讲者:Ka Yan Lai | 伊利沙伯医院


胃肠道罕见肿瘤


1. 摘要号:219eP


研究名称(英文):

Prognostic Factors for Metastatic Gastrointestinal Stromal Tumors Treated with Cytoreductive Surgery: A Retrospective Cohort Study 

讲者:Haidong Zhang | 四川大学华西医院


其他


1. 摘要号:495P


研究名称(英文):Optimising Chemotherapy Tolerability in Older Gastrointestinal Cancer Patients with Initial Dose Reduction

讲者:Wendy W. Chan | 香港大学李嘉诚医学院


2. 摘要号:499P


研究名称(英文):Association of TACR1 genotype and response to olanzapine-containing antiemetic prophylaxis for chemotherapy

讲者:Winnie Yeo | 香港中文大学


3. 摘要号:505eP


研究名称(英文):Real World Efficacy of Anlotinib in Bevacizumab-Treated Gastrointestinal Cancers

讲者:陈锦章 | 南方医科大学南方医院


备注:如有遗漏或任何问题,请给我们留言~

(本网站所有内容,凡注明来源为“医脉通”,版权均归医脉通所有,未经授权,任何媒体、网站或个人不得转载,否则将追究法律责任,授权转载时须注明“来源:医脉通”。本网注明来源为其他媒体的内容为转载,转载仅作观点分享,版权归原作者所有,如有侵犯版权,请及时联系我们。)

1
收藏 分享